Only 5 cancer-specific targets have thus far been approved by the FDA for ADC-based therapy against solid tumors: human epidermal growth factor receptor 2 (1, 2), human trophoblast cell surface glycoprotein antigen 2 (TROP2) (3, 4), tissue factor (5, 6), nectin cell adhesion molecule 4 (nectin-4) (7, 8), and folate receptor α (9, 10). This evidence concerns the gene NECTIN4 and cancer.